For the year ending 2025-12-31, SPRO made $66,802K in revenue. $8,572K in net income. Net profit margin of 12.83%.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Total revenues | 66,802 | 47,977 | ||
| Research and development | 38,467 | 96,757 | ||
| General and administrative | 21,176 | 23,704 | ||
| Impairment of long-term asset | 587 | - | ||
| Severance and other employee costs | 258 | - | ||
| Restructuring | 258 | 877 | ||
| Total operating expenses | 60,488 | 121,338 | ||
| Income (loss) from operations | 6,314 | -73,361 | ||
| Interest income | 2,512 | 4,735 | ||
| Other income (expense), net | 7 | 60 | ||
| Total other income, net | 2,519 | 4,795 | ||
| Net income (loss) before income taxes | 8,833 | -68,566 | ||
| Income tax expense | 261 | - | ||
| Net income (loss) and comprehensive income (loss) | 8,572 | -68,566 | ||
| Basic EPS | 0.15 | -1.27 | ||
| Diluted EPS | 0.15 | -1.27 | ||
| Basic Average Shares | 56,020,363 | 54,037,917 | ||
| Diluted Average Shares | 59,039,225 | 54,037,917 | ||
Spero Therapeutics, Inc. (SPRO)
Spero Therapeutics, Inc. (SPRO)